首页> 外国专利> SYNERGIC PHARMACEUTICAL COMPOSITION, USEFUL FOR INHIBITING CORNEAL AND RETINAL NEOVASCULARIZATION (ANGIOGENESIS), AND IN OTHER ORGANS, IN A HUMAN BEING OR ANIMAL

SYNERGIC PHARMACEUTICAL COMPOSITION, USEFUL FOR INHIBITING CORNEAL AND RETINAL NEOVASCULARIZATION (ANGIOGENESIS), AND IN OTHER ORGANS, IN A HUMAN BEING OR ANIMAL

机译:协同药物组合物,用于抑制人类或动物体内的角膜和视网膜新生血管形成(血管生成)以及其他器官

摘要

A synergistic pharmaceutical composition useful for inhibiting corneal and retinal neovasculization (angiogenesis) and in other organs, in a human being or animal, characterized in comprising, in a pharmaceutically acceptable vehicle or carrier: 60 to 90 weight % Suramine, or the equivalent of one of the pharmaceutically acceptable salts thereof; and 40 to 10 weight % Bevacizumab; wherein said percentages are relative to the addition of weight of both active principals. Said synergistic pharmaceutical composition is under the form of an injectable composition by intravenous, intravitrea or subconjuntival means or under the form for topical administration.
机译:一种用于抑制人或动物的角膜和视网膜新血管形成(血管生成)和其他器官中的协同药物组合物,其特征在于在药学上可接受的媒介物或载体中包含:60-90重量%的苏拉明,或等价的一种其药学上可接受的盐; 40至10重量%贝伐单抗;其中所述百分比是相对于两种活性成分的重量的加和。所述协同药物组合物为通过静脉内,玻璃体内或结膜下方式可注射的组合物形式或局部给药形式。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号